ID   SNU-668 Ola-R
AC   CVCL_C1NC
SY   SNU-668/olaparib-resistant; Olaparib-resistant SNU-668
DR   cancercelllines; CVCL_C1NC
DR   Wikidata; Q114313043
RX   PubMed=32028591;
CC   Population: Korean.
CC   Selected for resistance to: ChEBI; CHEBI:83766; Olaparib.
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000177777; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Ser215Asn (c.644G>A); ClinVar=VCV000376662; Zygosity=Homozygous (from parent cell line).
CC   Derived from site: Metastatic; Ascites; UBERON=UBERON_0007795.
DI   NCIt; C5250; Gastric signet ring cell adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_5081 ! SNU-668
SX   Male
AG   63Y
CA   Cancer cell line
DT   Created: 22-09-22; Last updated: 05-10-23; Version: 5
//
RX   PubMed=32028591; DOI=10.3390/cancers12020334;
RA   Kim J.W., Min A., Im S.-A., Jang H., Kim Y.J., Kim H.-J., Lee K.-H.,
RA   Kim T.-Y., Lee K.W., Oh D.-Y., Kim J.-H., Bang Y.-J.;
RT   "TDP1 and TOP1 modulation in olaparib-resistant cancer determines the
RT   efficacy of subsequent chemotherapy.";
RL   Cancers (Basel) 12:334.1-334.17(2020).
//